Demographics and clinical characteristics of treated patients
| Characteristics . | Patients (n = 12) . |
|---|---|
| Median age (range), y | 63 (34-81) |
| Male:female | 7:5 |
| Infused/enrolled | 12/13 |
| ECOG performance status, no. % | |
| 0-1 | 7/12 |
| 2+ | 5/12 |
| Disease location | |
| Parenchymal | 11/12 |
| Leptomeningeal enhancement/CSF+ | 2/12 |
| Cell of origin | |
| Germinal center B-cell type | 1/12 |
| Nongerminal center B-cell type | 11/12 |
| Median no. of previous lines of antineoplastic therapy (range) | 4 (2-9) |
| Prior methotrexate-based regimen | |
| Yes | 12/12 |
| No | 0/12 |
| Prior thiotepa-based ASCT | |
| Yes | 3/12 |
| No | 9/12 |
| BTKi refractory | |
| Yes | 12/12 |
| No | 0/12 |
| IMiD refractory* | |
| Yes | 4/12 |
| No | 8/12 |
| TEDDI-R refractory | |
| Yes | 6/12 |
| No | 6/12 |
| Prior radiotherapy | |
| Yes | 4/12 |
| No | 8/12 |
| Bridging therapy (including high-dose steroids) | |
| Yes | 12/12 |
| No | 0/12 |
| Median vein-to-vein time, d | 33 (27-37) |
| Characteristics . | Patients (n = 12) . |
|---|---|
| Median age (range), y | 63 (34-81) |
| Male:female | 7:5 |
| Infused/enrolled | 12/13 |
| ECOG performance status, no. % | |
| 0-1 | 7/12 |
| 2+ | 5/12 |
| Disease location | |
| Parenchymal | 11/12 |
| Leptomeningeal enhancement/CSF+ | 2/12 |
| Cell of origin | |
| Germinal center B-cell type | 1/12 |
| Nongerminal center B-cell type | 11/12 |
| Median no. of previous lines of antineoplastic therapy (range) | 4 (2-9) |
| Prior methotrexate-based regimen | |
| Yes | 12/12 |
| No | 0/12 |
| Prior thiotepa-based ASCT | |
| Yes | 3/12 |
| No | 9/12 |
| BTKi refractory | |
| Yes | 12/12 |
| No | 0/12 |
| IMiD refractory* | |
| Yes | 4/12 |
| No | 8/12 |
| TEDDI-R refractory | |
| Yes | 6/12 |
| No | 6/12 |
| Prior radiotherapy | |
| Yes | 4/12 |
| No | 8/12 |
| Bridging therapy (including high-dose steroids) | |
| Yes | 12/12 |
| No | 0/12 |
| Median vein-to-vein time, d | 33 (27-37) |
ECOG, Eastern cooperate oncology group performance status; TEDDI-R, temozolomide, etoposide, Doxil, dexamethasone, ibrutinib, and rituximab.
4 patients received IMiD as part of venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide.